ライフサイエンスコーパス: aortic stenosis

1 er and surgical aortic valve replacement for aortic stenosis.

2 ood biomarkers were studied in patients with aortic stenosis.

3 TAVR for bicuspid vs tricuspid aortic stenosis.

4 a risk factor for cardiovascular disease and aortic stenosis.

5 and PAD risk factors overlap with those for aortic stenosis.

6 utcomes in patients with asymptomatic severe aortic stenosis.

7 sk, and many intermediate-risk patients with aortic stenosis.

8 n left ventricular biopsies of patients with aortic stenosis.

9 ld not be made because of concomitant severe aortic stenosis.

10 -risk study patients with severe symptomatic aortic stenosis.

11 e PET/MRI and PET/CT data of 6 patients with aortic stenosis.

12 cision making, and survival in patients with aortic stenosis.

13 /=60 years across 37 advanced economies have aortic stenosis.

14 management of high-risk patients with severe aortic stenosis.

15 of disease severity even in patients with HG aortic stenosis.

16 BPs increased risk in patients with moderate aortic stenosis.

17 eters for defining high risk in asymptomatic aortic stenosis.

18 burden in patients with asymptomatic severe aortic stenosis.

19 e disease (CAVD) is the most common cause of aortic stenosis.

20 size for outcome prediction in asymptomatic aortic stenosis.

21 echocardiograms reported moderate or greater aortic stenosis.

22 d therapy in HR and inoperable patients with aortic stenosis.

23 ng on the medical treatment of patients with aortic stenosis.

24 patients with hypertrophic cardiomyopathy or aortic stenosis.

25 measure disease activity and progression in aortic stenosis.

26 and therapeutic decision-making processes in aortic stenosis.

27 sk operable patients with symptomatic severe aortic stenosis.

28 ercise and hyperemia in patients with severe aortic stenosis.

29 tive aortic regurgitation without coexisting aortic stenosis.

30 odynamic improvement in patients with severe aortic stenosis.

31 to low-risk patients with symptomatic severe aortic stenosis.

32 of aortic valve area in patients with severe aortic stenosis.

33 ry disease is common in patients with severe aortic stenosis.

34 erred for patients with cirrhosis and severe aortic stenosis.

35 patients with chronic heart failure (HF) and aortic stenosis.

36 d validity of CT-FFR in patients with severe aortic stenosis.

37 (Medtronic, n=4103) for treatment of native aortic stenosis.

38 s not been validated in patients with severe aortic stenosis.

39 al class II or higher, and had severe native aortic stenosis.

40 y and reinterventions for concomitant valvar aortic stenosis.

41 er heart valves in the treatment of bicuspid aortic stenosis.

42 tion could predict outcomes in patients with aortic stenosis.

43 is safe and feasible in patients with severe aortic stenosis.

44 of ischemia, hypertensive heart disease, and aortic stenosis.

45 theter aortic valve replacement for bicuspid aortic stenosis.

46 n for older patients with symptomatic severe aortic stenosis.

47 enhancement mass compared with high-gradient aortic stenosis.

48 versus without FR but lower in high-gradient aortic stenosis (13.3+/-10.2 versus 10.5+/-7.5 versus 4.

49 gnificantly higher for bicuspid vs tricuspid aortic stenosis (2.5% vs 1.6%; HR, 1.57 [95% CI, 1.06-2.

50 Of 81 822 consecutive patients with aortic stenosis (2726 bicuspid; 79 096 tricuspid), 2691

51 001), whereas women were more likely to have aortic stenosis (34.5% versus 44.1%, P<0.001).

52 nd without FR as compared with high-gradient aortic stenosis (35.25+/-9.75 versus 32.93+/-11.00 versu

53 on (622 [33.1%] vs 57 [24.1%], P < .001) and aortic stenosis (728 [38.7%] vs 51 [21.5%], P < .001).

54 isolated cardiac abnormalities, such as mild aortic stenosis; a similar proportion consider these can

55 Bicuspid aortic stenosis accounts for almost 50% of patients unde

56 ic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement

57 Myocardial tissue from patients with aortic stenosis also showed evidence of UPR(mt) activati

58 our understanding of the pathophysiology of aortic stenosis and as a biomarker end point in clinical

59 re acquired in 30 subjects (15 patients with aortic stenosis and associated secondary hypertrophic ca

60 ears, in a real-world population with severe aortic stenosis and at low and intermediate risk, sugges

61 al mechanical intervention for patients with aortic stenosis and concomitant reduced ejection fractio

62 as a valid alternative for the treatment of aortic stenosis and excellent valve hemodynamic results

63 itoring of patients with asymptomatic severe aortic stenosis and help to validate current guidelines

64 replacement (SAVR) for patients with severe aortic stenosis and high surgical risk.

65 Patients with severe, symptomatic aortic stenosis and high/intermediate surgical risk were

66 , 2016, 203 patients with severe symptomatic aortic stenosis and increased surgical risk, as determin

67 e replacement (SAVR) in patients with severe aortic stenosis and intermediate or high surgical risk.

68 ic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk.

69 patients across 12 centers with symptomatic aortic stenosis and large aortic annuli underwent transc

70 y used in high-risk patients with coexisting aortic stenosis and LM disease.

71 We randomly assigned patients with severe aortic stenosis and low surgical risk to undergo either

72 Valves) randomized 1000 patients with severe aortic stenosis and low surgical risk to undergo either

73 In patients with severe aortic stenosis and low surgical risk, TAVR with the SAP

74 ntion) trial, all-comer patients with severe aortic stenosis and lower surgical risk for mortality we

75 A total of 1767 patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease

76 90 mm Hg in these patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease

77 For patients with asymptomatic severe aortic stenosis and normal left ventricular function, cu

78 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ejection

79 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ejection

80 ,490 patients (544 women [37%]), with severe aortic stenosis and preserved left ventricular ejection

81 l history of patients with medically managed aortic stenosis and preserved left ventricular function

82 clusions In patients with severe symptomatic aortic stenosis and prohibitive surgical risk, the estim

83 ated with a higher prevalence of significant aortic stenosis and regurgitation.

84 current available data on stress testing in aortic stenosis and subsequently summarizes its potentia

85 that lowering Lp(a) will reduce progression aortic stenosis and the need for aortic valve replacemen

86 Depending of the severity of the aortic stenosis and the presence of concomitant heart di

87 siology and the coronary microcirculation in aortic stenosis and their impact on myocardial remodelin

88 onsecutive patients with symptomatic, severe aortic stenosis and transthoracic echocardiography pre-

89 Patients had severe aortic stenosis and were at increased surgical risk base

90 valve replacement in patients who had severe aortic stenosis and were at low surgical risk.

91 tion, 817 had aortic regurgitation, 471 with aortic stenosis, and 193 with mild mitral stenosis.

92 act of small aortic annulus in patients with aortic stenosis, and evaluate the different therapeutic

93 ft ventricular hypertrophy, cardio-oncology, aortic stenosis, and ischemic heart disease.

94 betes, hypertension, iron deficiency anemia, aortic stenosis, and prior bariatric surgery.

95 ral TAVR for treatment of symptomatic severe aortic stenosis, and who were deemed to be at increased

96 70 patients with BAV undergoing surgery for aortic stenosis (aorta diameter </=45 mm: BAVnon-dil or

97 hirty-nine patients with asymptomatic severe aortic stenosis (aortic valve area <1 cm(2), peak jet ve

98 dable transcatheter heart valves in bicuspid aortic stenosis are lacking.

99 reatment options for advanced or symptomatic aortic stenosis are limited to traditional surgical or p

100 c valve replacement (SAVR) for patients with aortic stenosis are unclear.

101 For patients with severe aortic stenosis (AS) and coronary artery disease (CAD),

102 The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) inc

103 Older patients with severe aortic stenosis (AS) are increasingly identified as havi

104 cular (LV) systolic dysfunction and moderate aortic stenosis (AS) are more frequent with advancing ag

105 In patients with severe aortic stenosis (AS) at intermediate surgical risk, trea

106 In patients with severe aortic stenosis (AS) at intermediate surgical risk, trea

107 In patients with severe aortic stenosis (AS) at low surgical risk, treatment wit

108 introduces a study on the classification of aortic stenosis (AS) based on cardio-mechanical signals

109 Severe aortic stenosis (AS) can manifest as exertional angina e

110 Aortic stenosis (AS) contributes to cardiovascular morta

111 The management of patients with aortic stenosis (AS) crucially depends on accurate diagn

112 on of patients with low-gradient (LG) severe aortic stenosis (AS) despite preserved left ventricular

113 Patients with severe aortic stenosis (AS) have repeat hospitalizations for mu

114 ve VHD was present in 5219 patients (72.0%): aortic stenosis (AS) in 2152 patients (41.2% of native V

115 ) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice.

116 Low-flow (LF) severe aortic stenosis (AS) is an independent predictor of mort

117 RATIONALE: Calcific aortic stenosis (AS) is characterized by calcium deposit

118 Calcific aortic stenosis (AS) is characterized by calcium deposit

119 Aortic stenosis (AS) is one of the most common valvular

120 Aortic stenosis (AS) leads to variable stress for the le

121 Severe aortic stenosis (AS) most often presents with reduced ao

122 Patients with severe aortic stenosis (AS) often have coronary artery disease.

123 xed aortic valve disease (MAVD) and isolated aortic stenosis (AS) or aortic regurgitation (AR) has no

124 vention in patients with asymptomatic severe aortic stenosis (AS) remains controversial.

125 Chronic kidney disease (CKD) and aortic stenosis (AS) share many risk factors.

126 Among the first 72,631 patients with severe aortic stenosis (AS) treated with TAVR enrolled in the S

127 therapeutic option for patients with severe aortic stenosis (AS) who are at prohibitive, high, or in

128 ta suggesting poor survival in patients with aortic stenosis (AS) who do not undergo treatment are la

129 spectively enrolled 105 patients with severe aortic stenosis (AS) who underwent TAVR as well as blood

130 Background Paradoxical low-flow (LF) severe aortic stenosis (AS) with preserved left ventricular eje

131 Valve morphology, aortic stenosis (AS), and aortic insufficiency (AI) have

132 tablished outcome predictor in patients with aortic stenosis (AS), but the prognostic impact of right

133 In severe aortic stenosis (AS), patients often show extra-aortic v

134 a major benefit in high-gradient (HG) severe aortic stenosis (AS), the results in low-gradient (LG, m

135 replacement (SAVR) for patients with severe aortic stenosis (AS).

136 included changes in the definition of severe aortic stenosis (AS).

137 is associated with an increased incidence of aortic stenosis (AS).

138 cm(2) is a defining characteristic of severe aortic stenosis (AS).

139 is involved in initiation and progression of aortic stenosis (AS).

140 rdiovascular risk factors and development of aortic stenosis (AS).

141 isturbed flow as it occurs, for instance, in aortic stenosis (AS).

142 role of cardiac magnetic resonance (CMR) in aortic stenosis (AS).

143 d effective therapy for patients with severe aortic stenosis (AS).

144 tal outcome have been reported in women with aortic stenosis (AS).

145 improve risk stratification in patients with aortic stenosis (AS).

146 le in asymptomatic patients with very severe aortic stenosis (AS); however, the definition of very se

147 ricular tissue was procured in patients with aortic stenosis (AS, n=9) and dilated cardiomyopathy (DC

148 between patients with bicuspid and tricuspid aortic stenosis at 30 days (2.6% vs 2.5%; hazard ratio [

149 diate-risk patients with severe, symptomatic aortic stenosis at 57 centers.

150 ibility study including patients with severe aortic stenosis at high surgical risk undergoing transfe

151 cal AVR (SAVR) for patients with symptomatic aortic stenosis at increased operative risk.

152 Patients with severe aortic stenosis at increased risk for surgery had improv

153 In patients with severe aortic stenosis at increased risk for surgery, self-expa

154 In patients with severe aortic stenosis at increased surgical risk, TAVR was ass

155 (TAVR) for patients with severe symptomatic aortic stenosis at intermediate surgical risk, TAVR volu

156 ternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a di

157 l-accepted option for treating patients with aortic stenosis at intermediate to high or prohibitive s

158 real-world propensity-matched patients with aortic stenosis at low and intermediate risk.

159 ess TAVI in patients with symptomatic severe aortic stenosis at low operative risk have set the stage

160 Our cohort consisted of patients with aortic stenosis at low surgical risk with a mean age of

161 rgoing isolated aortic valve replacement for aortic stenosis at Mayo Clinic Hospital in Rochester, Mi

162 data to describe trends in mortality due to aortic stenosis between 2008 and 2017, when use of trans

163 surgical aortic valve replacement for severe aortic stenosis between 2012 and 2014 at our institution

164 l AVR (SAVR), or conservative management for aortic stenosis between 2015 and 2017, using overlap pro

165 ic valve replacement (TAVR) in patients with aortic stenosis, but the presence of persistent fibrosis

166 Calcific aortic stenosis (cAS) affects 3% of individuals aged >75

167 dies suggest that approximately one-third of aortic stenosis cases are associated with highly elevate

168 urate measure of AVA in patients with severe aortic stenosis compared to AVA(Fick) measured using a m

169 en presented more often with moderate/severe aortic stenosis compared with men.

170 ntions, in particular for concomitant valvar aortic stenosis compared with patients with WBS.

171 rticular importance for patients with severe aortic stenosis considering transcatheter aortic valve r

172 theter Heart Valve in Low-Risk Patients With Aortic Stenosis) CT substudy randomized 435 patients wit

173 Patients with severe aortic stenosis deemed at increased risk for surgery by

174 We evaluated 1023 patients with severe aortic stenosis deemed high or extreme risk for surgery

175 Outcomes of TAVR in bicuspid aortic stenosis depend on valve morphology.

176 m reviewed all moderate- or greater-severity aortic stenosis echocardiography studies with concomitan

177 ge in the management of patients with severe aortic stenosis, especially in elderly women, where it i

178 This issue provides a clinical overview of aortic stenosis, focusing on screening, diagnosis, treat

179 n, in intermediate-risk patients with severe aortic stenosis given transcatheter aortic valve replace

180 tenosis, patients with bicuspid vs tricuspid aortic stenosis had no significant difference in 30-day

181 The definition of severe aortic stenosis has classically and retrospectively been

182 er aortic valve replacement for treatment of aortic stenosis has now become an accepted alternative t

183 renal disease on hemodialysis (ESRD-HD) and aortic stenosis have poor prognosis.

184 ately one third of patients with symptomatic aortic stenosis have reduced left ventricular ejection f

185 e (HR: 1.7; 95% CI: 1.04 to 2.60; p = 0.03), aortic stenosis (HR: 2.9; 95% CI: 1.5 to 5.4; p < 0.001)

186 diate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (pe

187 symptomatic severe aortic stenosis, moderate aortic stenosis in combination with heart failure with r

188 ystem in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects

189 ystem in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects

190 alve replacement (TAVR) for the treatment of aortic stenosis in high- and intermediate-risk patients,

191 e US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery a

192 Current guidelines define severe aortic stenosis in patients with aortic valve area norma

193 ter aortic valve replacement (TAVR) to treat aortic stenosis in the United States is growing, yet lit

194 ely to prevent abdominal aortic aneurysm and aortic stenosis, in addition to CAD and other atheromato

195 r early and midterm outcomes for adults with aortic stenosis, including those at low to intermediate

196 as to determine whether FAV for midgestation aortic stenosis increases survival from fetal diagnosis

197 Aortic stenosis is 1 of the most common heart valve dise

198 Aortic stenosis is a heterogeneous disorder.

199 Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis.

200 3 in intermediate-risk patients with severe aortic stenosis is associated with low mortality, stroke

201 Prevalence of calcific aortic stenosis is growing in ageing populations.

202 r aortic valve replacement (TAVR) for severe aortic stenosis is growing rapidly.

203 asymptomatic to symptomatic state in severe aortic stenosis is often difficult to assess.

204 replacement; however, before symptoms occur, aortic stenosis is preceded by a silent, latent phase ch

205 Aortic stenosis is the most common valvular heart diseas

206 Aortic stenosis is the most frequent valvular heart dise

207 tients with classical low-flow, low-gradient aortic stenosis (LFLG-AS) and its association with left

208 Low-gradient severe aortic stenosis (LGSAS) with preserved ejection fraction

209 -stage lung disease in the setting of severe aortic stenosis, likely representing a better alternativ

210 Aortic stenosis may contribute to cardiorenal syndrome t

211 pressure goals in patients with a history of aortic stenosis may need to be redefined.

212 The new protocol improved aortic stenosis mean gradient agreement between echocard

213 reported healthy controls and patients with aortic stenosis, mitral regurgitation, and left ventricu

214 dent coronary artery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillati

215 uited 102 participants to 5 groups: moderate aortic stenosis (ModAS) (n=13), SevAS, left ventricular

216 of an increased dilatation rate were severe aortic stenosis, moderate and severe aortic regurgitatio

217 d aortic valve stenosis, asymptomatic severe aortic stenosis, moderate aortic stenosis in combination

218 In ESRD-HD patients with aortic stenosis, mortality was lower in the short-term w

219 d the most common indication for surgery was aortic stenosis (n = 225 [72.6%]).

220 Coronary artery disease and aortic stenosis often coexist.

221 least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve surgery (bioprosthesis r

222 have implications on lifetime management of aortic stenosis, particularly in younger patients.

223 R), reoperation to relieve severe prosthetic aortic stenosis (PAS) is increasing.

224 Studies of TAVR in low-flow severe aortic stenosis patients have demonstrated that TAVR has

225 e transcatheter aortic valve replacement for aortic stenosis, patients with bicuspid vs tricuspid aor

226 investigating the role of TAVR in lower-risk aortic stenosis populations, in patients with aortic reg

227 We included 289 patients with asymptomatic aortic stenosis, preserved ejection fraction, and AVA<1.

228 theory, specific medical therapy should halt aortic stenosis progression, reduce its hemodynamic repe

229 n prevalence, valve morphology, dysfunction (aortic stenosis/regurgitation), aortopathy, and complica

230 d treatment of patients with low-flow severe aortic stenosis remains challenging.

231 R) on kidney function stage in patients with aortic stenosis remains poorly understood.

232 The management of aortic stenosis rests on accurate echocardiographic diag

233 h gradient and low flow high gradient severe aortic stenosis (SAS) with no or minimal symptoms.

234 Why some but not all patients with severe aortic stenosis (SevAS) develop otherwise unexplained re

235 patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aor

236 rance status, left ventricular function, and aortic stenosis severity between patients with (n = 202)

237 ave shown that among high-risk patients with aortic stenosis, survival rates are similar with transca

238 Supravalvular aortic stenosis (SVAS) is a narrowing of the aorta cause

239 m cells (iPSCs) to investigate supravalvular aortic stenosis (SVAS) patients and/or elastin mutant mi

240 riants in ELN cause nonsyndromic supravalvar aortic stenosis (SVAS).

241 In patients with symptomatic severe aortic stenosis, TAVI has now been explored across the e

242 In aortic stenosis, therapeutic decision essentially depend

243 relief of valve obstruction in patients with aortic stenosis, there is an independent association bet

244 FAV) may prevent progression of midgestation aortic stenosis to hypoplastic left heart syndrome.

245 ynamic load may be important in asymptomatic aortic stenosis to identify patients at risk.

246 ly enrolled patients with symptomatic severe aortic stenosis to undergo TAVR using a commercially ava

247 ndomized 435 patients with low-surgical-risk aortic stenosis to undergo transcatheter aortic valve re

248 rom the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what blood pressure (BP) woul

249 of nonsurgical mechanical interventions for aortic stenosis (transcatheter aortic valve replacement)

250 ted with worse prognosis among patients with aortic stenosis treated medically or with surgical aorti

251 d were measured in 2141 patients with severe aortic stenosis treated with TAVR in the PARTNER I trial

252 prospective registry of patients with severe aortic stenosis treated with the commercially available

253 ctiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) study.

254 ctiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) showed that mortality at 1 ye

255 igh-risk and inoperable patients with severe aortic stenosis undergoing a transcatheter aortic valve

256 d 7 nondiabetic cardiomyopathy patients with aortic stenosis undergoing aortic valve replacement.

257 zed clinical trial of patients with calcific aortic stenosis undergoing SAVR at 18 North American cen

258 actions on mortality in patients with severe aortic stenosis undergoing surgical aortic valve replace

259 al trial in higher-risk patients with severe aortic stenosis undergoing TAVI at the University of Lei

260 Among patients with severe aortic stenosis undergoing TAVI, the use of a cerebral p

261 In patients with severe aortic stenosis undergoing TAVR, even with baseline impa

262 increasing number of patients with bicuspid aortic stenosis undergoing TAVR.

263 sfunction (DD) and outcomes in patients with aortic stenosis undergoing transcatheter aortic valve re

264 In patients with aortic stenosis undergoing transcatheter aortic valve re

265 Among patients with aortic stenosis undergoing transfemoral transcatheter ao

266 orial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral transcatheter ao

267 al of 616 patients age <70 years and without aortic stenosis underwent elective aortic root surgery (

268 Fifteen patients with aortic stenosis underwent repeated 18F-fluoride PET-CT.

269 1+/-8.4 years; 83% men] and 24 high-gradient aortic stenosis used as controls) undergoing dobutamine

270 In aortic stenosis, valvulo-arterial impedance (Zva) estima

271 The presence of aortic stenosis was also associated with cardiac decompe

272 core matched pairs of bicuspid and tricuspid aortic stenosis were analyzed (median age, 74 years [int

273 A total of 8107 ESRD-HD patients with aortic stenosis were included, 4130 (50%) underwent TAVR

274 xtreme risk patients with severe symptomatic aortic stenosis were recruited from 52 medical centres e

275 qual to III+ aortic regurgitation and severe aortic stenosis were seen in 37% and 10%, respectively.

276 e to severe aortic regurgitation, and severe aortic stenosis were seen in 7%, 18%, and 2%, whereas 91

277 Patients had severe aortic stenosis, were treated with TAVR or SAVR, and wer

278 therapy in symptomatic patients with severe aortic stenosis, whereas the management of asymptomatic

279 (SAVR) for patients with symptomatic severe aortic stenosis who are at high risk of perioperative mo

280 ternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is k

281 is standard therapy for patients with severe aortic stenosis who are at high surgical risk.

282 ternative to surgery in patients with severe aortic stenosis who are at increased risk for death from

283 Among patients with aortic stenosis who are at intermediate or high risk for

284 ay clinical outcomes in patients with severe aortic stenosis who are at intermediate risk of surgical

285 out comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk.

286 art valve (THV) size in patients with severe aortic stenosis who are suboptimal surgical candidates.

287 rapidly evolving treatment for patients with aortic stenosis who require valve replacement.

288 105 consecutive patients with cirrhosis and aortic stenosis who underwent TAVR (n = 55) or SAVR (n =

289 Patients from 10 institutions with severe aortic stenosis who underwent TAVR between August 2007 a

290 l cohort study included patients with severe aortic stenosis who underwent TAVR in the Society of Tho

291 Among patients with aortic stenosis who were at intermediate surgical risk,

292 In patients with severe aortic stenosis who were at low surgical risk, TAVR with

293 Among patients with severe aortic stenosis who were at low surgical risk, the rate

294 volved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory Minneapo

295 with end-stage lung disease and significant aortic stenosis who were successfully bridged to lung tr

296 llion (95% CI, 2.2-4.4) patients have severe aortic stenosis with 1.9 million (95% CI, 1.3-2.6) eligi

297 ibes the epidemiology and pathophysiology of aortic stenosis with heart failure and reduced ejection

298 ding of severe (aortic valve area <=1 cm(2)) aortic stenosis with preserved left ventricular ejection

299 Renal dysfunction is intricately linked to aortic stenosis, with over 25% patients presenting for t

300 TA-TAVR included more postdilatations, pure aortic stenosis without regurgitation, and possibly more